Business

Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced the recent appointment of four distinguished experts to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board: Scott A. Sands, Ph.D., Associate Professor of Medicine at Harvard Medical School and Director of the Sleep Apnea Transla

articleIncannex Healthcare Inc.June 3, 20259/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-inc-expands-ihl-113000098
Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

About this update from Incannex Healthcare Inc.

[{"type":"image","alt":"Incannex Healthcare","displaySize":"","headline":null,"caption":"Incannex Healthcare","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JtZ_G8jXkVENc6BFL9UpGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7","width":300,"height":50}},"lazy":false},{"type":"text","content":"NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced the recent appointment of four distinguished experts to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board:","length":379,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Scott A. Sands, Ph.D., Associate Professor of Medicine at Harvard Medical School and Director of the Sleep Apnea Translational Physiology Group in the Division of Sleep and Circadian Disorders at Brigham and Women’s Hospital.","length":225,"tagName":"p"}]},{"val":[{"type":"text","content":"Ali Azarbarzin, Ph.D., Associate Professor of Medicine at Harvard Medical School and a lead investigator at Brigham and Women’s Hospital.","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Lora J. McGill, M.D., FAAN, board-certified neurologist and clinical researcher based in Memphis, Tennessee.","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Nancy Collop, M.D., Director of the Emory Sleep Center and Professor of Medicine and Neurology at Emory School of Medicine.","length":123,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":593,"olType":false},{"type":"text","content":"“These four outstanding leaders bring incredible depth and insight to our IHL-42X Clinical Advisory Board as we continue our work to create an unprecedented treatment to a major health concern.” said Dr. Lou Barbato, Chief Medical Officer of Incannex. “Their expertise spans academic and clinical research leadership in sleep apnea, and we are confident the board will provide an invaluable foundation as we continue to advance IHL-42X, an Oral Once-Daily Treat...

More updates from Incannex Healthcare Inc.

Harvard Medical SchoolSleep ApneaIncannex Healthcare Inc.Professor of MedicineEmory School of MedicineSleep Medicineclinical researchScott A. Sandsclinical researcherBrigham and Women’s HospitalSleep